|
|||||
|
|
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database |
|
| Authors: | Best Jennie H Hoogwerf Byron J Herman William H Pelletier Elise M Smith Daniel B Wenten Made Hussein Mohamed A |
| Institution: | Amylin Pharmaceuticals, San Diego, California, USA. jennie.best@amylin.com |
| Abstract: | |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |